

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Effectiveness of Self-testing Kits Availability on Improving HIV Testing Frequency for Chinese Men Who Have Sex with Men and Their Sexual Partners: A Protocol for A Multicenter Randomised Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024423
Article Type:	Protocol
Date Submitted by the Author:	26-May-2018
Complete List of Authors:	Zhang, Ci; Central South University Xiangya School of Nursing, Li, Xianhong; Central South University Xiangya School of Nursing Koniak-Griffin, Deborah; UCLA School of Nursing Goldsamt, Lloyd; NYU College of Nursing Zhou, Jing; Central South University Xiangya School of Nursing
Keywords:	HIV, men who have sex with men (MSM), HIV self-testing (HIVST), sexual partner testing, HIV testing frequency

SCHOLARONE™
Manuscripts

Running title: A RCT STUDY ON HIV SELF-TESTING EFFECTIVENESS

Effectiveness of Self-testing Kits Availability on Improving HIV Testing

Frequency for Chinese Men Who Have Sex with Men and Their Sexual Partners:

A Protocol for A Multicenter Randomised Controlled Trial

Ci Zhang¹, Xianhong Li^{1*}, Deborah Koniak-Griffin², Lloyd Goldsamt³, Jing Zhou¹

1 Xiangya Nursing School of Central South University, Changsha, China

2 UCLA School of Nursing, Los Angeles, USA

3 NYU College of Nursing, New York, USA

*Corresponding author: 172 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China;

xianhong_li228@hotmail.com; +86 0731-82650264 (Xianhong Li)

Word count: 4080

Abstract

Introduction: HIV epidemic is increasing among men who have sex with men (MSM) in China, yet HIV testing uptake remains low. As an emerging approach, HIV self-testing (HIVST) has the potential to promote HIV testing coverage and frequency in this population. However, evidence of the effectiveness on implementation of HIVST among Chinese MSM and their sexual partners is scarce.

Methods and analysis: The randomized controlled trial will be performed in Changsha, Changde, Shaoyang, and Yiyang, Hunan province, China, recruiting 184 recent testers (men who had at least one HIV test within the past 2 years) and 26 non-recent testers (men who did not have HIV tests within 2 years or never had an HIV test). Eligible men will be randomly divided 1:1 into two groups: intervention (with free HIVST kits plus site-based HIV testing services) and control (site-based HIV testing services only). Participants in the intervention group will be provided with two free finger-prick-based HIVST kits, and can apply for two to four kits every 3 months for 1 year.

Participants in both groups will complete questionnaires via WeChat at five separate times: baseline, 3rd, 6th, 9th, and 12th month. The primary outcome is the mean number of HIV tests for MSM over the 12-month study period. The secondary outcome is the mean number of HIV tests for sexual partners of MSM over the 12-month study period. The tertiary outcomes are the self-reported proportion of consistent condom usage for anal sex, and the numbers of sexual partners during the

12-month study period.

Ethics and dissemination: The study has been approved by the Institutional Review Board of Behavioral and Nursing Research in Xiangya School of Nursing of Central South University, China (2018002). Study results will be disseminated through conferences and academic journals.

Trial registration number: Chinese Clinical Trial Registry (ChiCTR1800015584).

Strengths and limitations of this study

- No study has reported effectiveness of free HIV self-testing (HIVST) kits availability on increasing HIV testing frequency among men who have sex with men (MSM) in China.
- One major innovation of this study is to determine effectiveness of distribution of HIVST kits from MSM to their sexual partners, which will provide evidence to guide the application of HIVST to promote partner testing and improve HIV testing coverage.
- Findings from this study will have potential to help policymakers to scale up the HIVST approach to reach more high-risk individuals and could be utilized to develop contextualized HIV prevention strategies for Chinese MSM.
- In this longitudinal study, maintaining MSM for 12 months is difficult and thus loss to follow-up is possible.
- Data about sexual partners' use of HIVST kits which will be obtained indirectly

by report of MSM may be inclined to bias.

Introduction

Globally, HIV remains a major public health threat, with a total of approximately 36.7 million individuals infected at the end of 2015.¹ Despite great efforts to improve HIV prevention and treatment, the annual number of newly HIV-infected individuals remains around 2.2 million over the past 5 years.² Notably, the transmission rate of HIV among men who have sex with men (MSM) is alarmingly high globally, accounting for 30% of all infected individuals.³ China has also faced a severe HIV epidemic among MSM,⁴ with the HIV prevalence among MSM increasing nearly 9 times from 0.9% in 2003 to 8.0% in 2015,^{5,6} and 25.5 % of newly infected individuals were attributed to MSM in 2017.⁷

In 2014, UNAIDS set up the "90-90-90" goal aiming to control the HIV epidemic by 2020, with 90% of HIV-infected individuals getting tested and diagnosed, 90% of diagnosed individuals receiving treatment, and 90% of individuals under treatment achieving viral suppression.⁸ However, only 60% of HIV-positive individuals have been tested around the world,³ far from reaching the first goal. The situation in China is similar. A recent meta-analysis showed that 62% of MSM had not taken an HIV test over the past 12 months, and nearly 50% had never been tested in their lifetime.⁹ Lack of adequate HIV testing, multiple sexual partners, and frequent high-risk sexual behaviors have exacerbated HIV prevalence among MSM and may lead to further transmission to the general population via sexual contacts with female sexual

1
2
3 partners.^{10 11} Moreover, late HIV testing and late antiretroviral treatment may increase
4 the probability of HIV/AIDS-related deaths.¹² Thus, it is essential to promote HIV
5 testing, especially among MSM.
6
7
8
9

10
11 As a complementary approach, HIV self-testing (HIVST) has significant potential
12 to scale up HIV testing coverage. It can be used by individuals to collect specimens
13 (their own blood or saliva), perform a test, and read the test results by themselves.¹³
14 With the characteristics of convenience, privacy, and confidentiality,¹⁴⁻¹⁶ HIVST may
15 be very attractive to MSM who are impacted by HIV/AIDS-related stigma and
16 discrimination; limited transportation; and/or reluctance to wait when taking the test
17 at the traditional sites, such as the Center for Disease Prevention and Control [CDC],
18 sites of voluntary counseling and testing services for AIDS, and hospitals.¹⁷ A recent
19 review indicated that HIVST kits had high acceptability (>67%) among MSM of the
20 14 included studies,¹⁸ not specific to oral fluid based or blood based. However, the
21 usage rate of HIVST kits was low in certain countries, with reported rates of 3.5% in
22 France, 6.1% in China, and 11.6% in the USA.¹⁹⁻²¹ The barriers to use included worry
23 about a positive result, the relatively high cost of kits, and concerns about correct
24 usage of the kits.²²
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Data released by UNAIDS (2017) underlines that reaching MSM and their
47 partners with HIV testing services may have the potential to control the HIV
48 epidemic.²³ In the United States, a randomized controlled trial (RCT) showed that the
49 availability of HIVST could increase HIV testing uptake among MSM.²⁴ A previous
50 RCT in Australia also indicated that HIVST could increase the HIV testing frequency
51
52
53
54
55
56
57
58
59
60

1
2
3 among MSM, especially in delayed testers (those who had never received HIV testing
4 or had not been tested within 2 years).²⁵ Moreover, a previous US study showed that
5
6 79%-91% of MSM were willing to distribute HIVST kits to their sexual partners.²⁶
7
8 Serostatus disclosure to their regular or casual sexual partners after testing with
9
10 HIVST kits would promote safe sexual practices if the testing results were
11
12 positive.^{27 28} Thus, distribution of HIVST kits from MSM to their sexual partners
13
14 could be an effective way to expand HIV testing and reduce high-risk sexual
15
16 behaviors among MSM.^{27 28}

17
18
19 In accordance with this strategy, a guideline on HIVST was issued by the WHO
20
21 in 2016 to promote HIV testing and partner disclosure.¹³ However, in the guideline,
22
23 there was only evidence from two RCTs to support the effectiveness of HIVST kits
24
25 for improving HIV testing frequency among MSM.^{24 25} Further research is urgently
26
27 needed to determine the effects of providing free HIVST kits on MSM and their
28
29 sexual partners in China.

30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Methods

Study objectives

This randomized controlled trial is designed to determine whether the distribution of HIVST in an intervention group compared to a control group improves the frequency of HIV testing among MSM (primary aim) and their sexual partners (male and female) (secondary aim). The study also aims to explore whether HIVST reduces high risk sexual behaviors of MSM (tertiary aim). Outcomes will be compared

1
2
3 between participants in the intervention and control groups who have histories of
4
5 recent and non-recent HIV testing.
6
7

8 9 **Study settings**

10
11 This study will be conducted in four cities within Hunan Province, namely
12
13 Changsha (the capital of the province), Changde, Shaoyang, and Yiyang. The settings
14
15 include urban and rural areas. Delivery services of free HIVST kits are unavailable
16
17 through any organizations in these cities. HIV prevalence in Hunan Province ranks 9th
18
19 nationally in mainland China.²⁹ The number of HIV/AIDS patients in Hunan Province
20
21 was about 24,000 in 2016, with 4,974 newly infected.³⁰ Notably, 64.8% of the new
22
23 patients were infected through male-to-male sexual intercourse.³⁰ In our unpublished
24
25 cross-sectional study, 37.7% of MSM had never tested for HIV in Hunan Province.
26
27
28
29
30

31 32 **Participants**

33
34 Two subgroups of MSM will be recruited: recent testers (men who had at least
35
36 one HIV test within the last 2 years) and non-recent testers (men who did not have
37
38 HIV tests within the last 2 years or never had a HIV test). Zuo An Cai Hong, a
39
40 gay-friendly community-based organization (CBO) ---- with seven sub-locations in
41
42 the participating settings of Hunan Province, will collaborate in this study. The CBO
43
44 provides rapid HIV tests, counseling, and referral for MSM, and it conducts around
45
46 1,500-2,000 HIV tests each year. Thus, the feasibility of the study recruitment is
47
48 supported.
49
50
51
52
53

54 55 **Inclusion criteria**

1
2
3
4 Individuals are eligible for participation if they meet the following criteria: (1)
5
6 male anatomy; (2) 18 years of age or older; (3) reporting condomless anal or oral sex
7
8 with men in the past 3 months; (4) HIV negative by rapid HIV testing at screening; (5)
9
10 planning to reside in Hunan Province during the next year; (6) possessing a
11
12 smartphone and adept in using WeChat; and (7) voluntarily agreeing to participate in
13
14 the study and provide written informed consent.
15
16
17

18 **Exclusion criteria**

19
20
21 Individuals will be excluded if they: (1) have a serious psychiatric illness, (2) are
22
23 participating in other research programs, or (3) cannot speak and/or read Chinese.
24
25
26

27 **Study procedure**

28 **Study design**

29
30
31 A multisite RCT design will be used to determine the effectiveness of HIVST on
32
33 improving HIV testing frequency among Chinese MSM and their sexual partners, and
34
35 to explore whether HIVST reduces high risk sexual behaviors of MSM in China.
36
37 Participants will be randomly assigned to intervention and control groups, with a 1:1
38
39 ratio. The intervention group will be provided with free HIV self-testing kits and
40
41 site-based HIV testing services for 1 year, and participants in the control group will
42
43 have access to site-based HIV testing for 1 year (the control group will also receive
44
45 the kits after the study concludes) (Fig. 1).
46
47
48
49
50
51
52

53 **Recruitment**

1
2
3
4 Participants will be recruited through posting of flyers (1) in the office and
5
6 waiting areas of the four study locations, and (2) on Blued (a social media site for
7
8 MSM), the instant online-chatting platform of QQ and WeChat (public number of Zuo
9
10 An Cai Hong). CBO staff also will provide study information to MSM who are
11
12 coming for testing or counseling. A WeChat account and a phone number will be
13
14 established solely for study online consultation and follow-up.
15
16

17
18
19 MSM who express interest in this study will be contacted by the research
20
21 assistant (RA) via WeChat or cellphone for purposes of scheduling an appointment at
22
23 the nearby sublocation of the CBO to complete the screening procedure and receive a
24
25 rapid HIV test following oral consents. Fig.1 presents the recruitment flow chart.
26
27

28
29
30
31
32 Figure1 Flow of recruitment and intervention.
33
34

35 **Randomization**

36
37
38 Securing of written informed consent will be obtained from eligible MSM prior
39
40 to randomization into the intervention group and control group. Computer-generated
41
42 randomized number tables developed by SPSS 18.0 will be used for this purpose. Two
43
44 separate randomized number tables will be used for recent testers and non-recent
45
46 testers.
47
48
49

50 **Blinding**

51
52
53
54 During the screening and informed consent procedure, the RAs will be blinded to
55
56
57

1
2
3
4 the randomization number tables, which will be sealed in opaque and sequentially
5
6 numbered envelopes. After screening procedure and written informed consent, the
7
8 envelope will be opened and the group assignment will be exposed to both the
9
10 participants and the RAs. Throughout the project, the data analyst will be blinded to
11
12 the group assignments.
13
14

15 16 **Intervention group**

17
18
19 Participants in the intervention group will have access to free HIVST kits in
20
21 addition to site-based HIV testing services. They will be encouraged to perform HIV
22
23 tests for themselves and their sexual partners using the HIVST kits. At enrollment,
24
25 participants will be provided two HIVST kits with detailed instructions and
26
27 information. Instructions and additional information will also be posted in the official
28
29 account of Zuo An Cai Hong on WeChat. Participants in the intervention group will
30
31 be asked to submit a photo of each test result, following which they can apply to
32
33 receive new kits. A cross-sectional study in China indicated that the mean number of
34
35 sexual partners of MSM was 4.79 during the past 6 months.³¹ Given the repeated tests,
36
37 distribution to sexual partners and the recommendation of 2-4 tests per year for
38
39 high-risk MSM,^{32 33} participants can apply for 2-4 kits every 3 months, and a
40
41 maximum of 12 kits for 1 year. For participants' convenience, these kits can be
42
43 obtained at study sites or through express delivery. With 24 hours' notice, the kits will
44
45 be delivered in private packages without any information about HIV/AIDS or testing
46
47 visible on the packaging. To encourage MSM to send back the photos of their results,
48
49 participants will be charged a 30¥ (the equivalent of \$5 USD) deposit for each kit,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 which will be returned immediately after the RA receives the result photos. Each kit
4
5
6 will be numbered sequentially on the outer packing before distribution for monitoring
7
8 purposes.
9

10 11 **The product of self-testing kits** 12

13
14 Selection of the type of HIVST kits (oral fluids from mouth swabs versus blood
15
16 samples from finger pricking) was made with consideration of research findings.
17
18 Previous studies indicate that 5%-10% of participants made procedural errors,^{34 35} and
19
20 10% requested additional help beyond the provided demonstration and instructions
21
22 when using oral self-testing kits.³⁵ Thus, a finger-prick based HIVST kit, a third
23
24 generation of Alere Determine HIV 1/2 rapid assay (Alere Medical Co., Ltd, Japan),
25
26 approved by the US Food and Drug Administration and China's State Food and Drug
27
28 Administration was selected for use in this study.^{36 37} This test can detect HIV 1/2
29
30 antibodies in blood specimens after 6 weeks since being infected by HIV.³ The
31
32 specimen is obtained by pricking a finger using a disposable peripheral blood needle
33
34 made by STERiLANCE in China. Blood is collected by EDTA capillary tube and
35
36 dropped on a specimen reaction zone of the HIVST kit, and then Alere Determine
37
38 Chase solution is added in the reaction zone.³⁸ The result can be read in 15-60
39
40 minutes.³⁸ The specificity and sensitivity of the Alere Determine HIV 1/2 are 99.68%
41
42 and 100%, respectively.³⁹ Every kit is accompanied by instructions including testing
43
44 procedure, interpretation of results, and notes. The HIVST is preliminary for
45
46 screening, and a positive result requires confirmation by enzyme-linked immunoassay
47
48 in the CDC laboratory.
49
50
51
52
53
54
55
56
57
58
59
60

Support hot lines

Participants will be able to contact RAs by WeChat or a 24-h telephone support line to obtain consultation on the HIVST administration and interpretation of results. Records will be maintained on the purpose of the consultation.

Follow-up of positive results

Participants testing themselves or their sexual partners positive on the HIVST results will be advised to inform the RAs by the 24-h telephone support hotline or WeChat. The RAs will provide additional consultation about positive results and treatment options for HIV positive individuals (including MSM and their sexual partners). Confirmatory laboratory testing will be advised for any positive results. Transfer services to the local CDC for further HIV testing and professional psychological counselling will be provided, as necessary.

Control group

Participants in the control group will receive usual care provided at the CDC, CBO-based rapid HIV testing sites, or local hospitals where they may receive HIV testing. After completion of the 12-month follow-up, these participants can obtain a free supply of HIVST kits for a 12-month period. The same procedure offered to the intervention group will be implemented after follow-up evaluations are completed.

Outcome measures

The primary outcome is the mean number of HIV tests received by MSM from

1
2
3
4 baseline to the 12-month evaluation. This number will be calculated based upon the
5
6 total number of HIVST kits and site-based HIV tests. The secondary outcome is the
7
8 mean number of HIV tests for sexual partners within 12 months reported by MSM,
9
10 using the same calculations. The tertiary outcomes are the frequency of consistent
11
12 condom usage for anal sex (never/sometimes/usually/always using condoms), and the
13
14 numbers of reported sexual partners during the past 12 months.
15
16
17

18 **Data collection**

19
20
21 Data will be collected anonymously through online questionnaires produced by
22
23 “sojump” (<http://www.sojump.com>), a professional online survey company, which has
24
25 a confidential contract with the study team to encrypt the data and ensure the safety
26
27 and privacy of the participants’ information. An account with *sojump* will be set up,
28
29 and the password will only be accessed by the RAs. Participants in the intervention
30
31 and control groups will receive and complete the questionnaires via WeChat five
32
33 times, at baseline and 3-, 6-, 9-, and 12-month follow-ups.
34
35
36
37
38

39
40 The content validity of the baseline questionnaire was obtained by expert review.
41
42 Included in this questionnaire are items related to social-demographic information,
43
44 HIV testing history (number of HIV tests, test results, and reasons for site-based HIV
45
46 tests/self tests), partner testing history (number of tests with HIVST kits distributed by
47
48 MSM and site-based HIV tests recommended by MSM, test results, and number of
49
50 sexual partners’ refusing to test), and high-risk sexual behavior history (number of
51
52 sexual partners, number of and reasons for condomless oral or anal sex), during the
53
54
55
56
57

1
2
3
4 past year and last 3 months. Two previously pilot-tested items assess HIV testing
5
6 self-efficacy (Cronbach's $\alpha = 0.74$) with statements about confidence in HIV
7
8 self-testing and confidence in regular HIV testing (every 6 months). Response choices
9
10 are based on a 10-point Likert-type scale ranging from 1 = not at all confident to 10 =
11
12 completely confident.
13
14

15
16 The follow-up questionnaires, to be administered at 3-month intervals, include
17
18 items from the baseline measure evaluating HIV testing, partner testing, high-risk
19
20 sexual behavior during the past 3 months, and self-efficacy for HIV testing.
21
22 Participants who report positive or uncertain results on HIVST will be asked whether
23
24 they have linked to care for confirmatory laboratory HIV testing.
25
26
27
28

29
30 At the 12-month follow-up, participants will also be asked questions about their
31
32 experiences with self-testing and their willingness to use HIVST kits in the future.
33
34 Compensation (\$16 per person per time) will be provided to participants for their time
35
36 spent filling out the questionnaires.
37
38

39
40 If any follow-up questionnaires are not been completed, we will remind
41
42 participants via WeChat and/or text messages three times at intervals of 1, 2, and 3
43
44 weeks after the questionnaires being sent.
45
46

47 **Statistical analysis plan**

48 **Analysis plan**

49
50
51 Analyses will be conducted using SPSS 18.0. Data will be imported directly to
52
53 SPSS18.0 from *sojump*, avoiding data inputting errors. Statistical results will be
54
55
56
57

1
2
3 reported with *p* values and 95% *CI* for the corresponding hypothesis tests. *P* values
4
5 <0.05 are considered statistically significant. Baseline characteristics of the two
6
7 groups will be compared. Analyses will be performed between the intervention and
8
9 control groups for recent and non-recent testers.
10
11
12

13
14 The primary analysis will compare the mean number of HIV tests within 12
15
16 months by using independent sample *t*-tests. At the end of the study, generalized
17
18 estimated equation models will be used to analyze the variation tendency of the mean
19
20 number of HIV tests every 3 months for participants. We will also use independent
21
22 sample *t*-tests to analyze the mean number of HIV tests for sexual partners of MSM.
23
24
25

26
27 The frequency of high-risk sexual behaviors every 3 months will be analyzed
28
29 using a generalized estimated equation model. The relationship between the results of
30
31 HIVST (positive, negative or uncertain) and condom use rate after the test will be
32
33 explored using logistic regression analysis. The trend of HIV testing self-efficacy will
34
35 be explored with generalized estimated equation models. The rate of positive
36
37 self-testing results and the linkage to care will be only analyzed descriptively.
38
39
40

41 42 **Sample size** 43 44

45 The target sample size was calculated using G-power 3.0⁴⁰ with a one-tailed test,
46
47 80% power, and a 5% significance level. Calculations of sample size were made with
48
49 consideration of previous research findings in China⁴¹ indicating the mean number of
50
51 HIV tests for recent testers was 1.35 tests per year. Guidelines recommend individuals
52
53 at high-risk have 2-4 HIV tests per year,^{32 33} thus an increase from 1.35 to 2 tests per
54
55
56
57
58
59
60

1
2
3 year [standard deviation: 1.61]⁴¹ is anticipated for recent testers. The mean number of
4
5 HIV tests for non-recent testers is 0.2 tests per year based upon findings of past
6
7 research in Australia.²⁵ Thus, we expect to detect an increase from 0.2 to 1 test per
8
9 year [standard deviation: 0.7]²⁵ for non-recent testers. Given a 20% missing rate, we
10
11 conservatively estimate 184 recent testers and 26 non-recent testers will help detect
12
13 the difference in HIV testing frequency between the two arms.
14
15
16
17

18 **Study schedule**

19
20
21
22 Two years (April 14 2018 - April 14 2019) will be needed to complete the study,
23
24 including 6 months to recruit participants, 1 year for follow-up and collecting data,
25
26 and 6 months to process the data and report.
27
28
29

30 **Patient and public involvement**

31
32
33 We took participants' priorities into account by conducting a interviews to
34
35 explore their experience and asking their preference for delivery methods. But
36
37 participants were not involved in the study design. In addition, they were not involved
38
39 in the study recruitment and conduction either. Participants have right to refuse to
40
41 participate in this study after accessing the burden of the intervention (including long
42
43 follow-up process and time spent in completing questionnaires for five times). All
44
45 participants will maintain rights to access services at the CDC or CBO. If the
46
47 effectiveness of HIVST was confirmed by the study, the results will be disseminated
48
49 to the study population.
50
51
52
53
54

55 **Ethics and dissemination**

1
2
3
4 The study has received an ethical approval from the Institutional Review Board
5
6 of Behavioral and Nursing Research in Xiangya School of Nursing of Central South
7
8 University, China (approval number 2018002). Moreover, the following measures will
9
10 be taken to meet ethical standards: (1) written informed consent from participants will
11
12 be required before enrollment and oral informed consent for rapid HIV testing at the
13
14 time of screening, and (2) personal information of participants will be stored in an
15
16 offline encrypted computer that can only be accessed by the research team. Results
17
18 from this study will be disseminated through conferences and academic journals.
19
20
21
22

23 **Trial registration**

24
25
26 The study has been registered with Chinese Clinical Trial Registry [trial ID:
27
28 ChiCTR1800015584, on April 9, 2018].
29
30
31

32 **Discussion**

33
34
35 The HIV epidemic is rapidly growing among MSM,³⁻⁵ yet HIV testing uptake
36
37 remains far below the recommended level in China and other countries.³⁻⁹ Due to
38
39 diverse socioeconomic status, the coverage of site-based HIV testing services differs
40
41 by country and region. As a complementary approach, HIVST has the potential to
42
43 expand availability of basic HIV testing services and broader HIV testing coverage.⁴²
44
45 However, HIVST has not been widely utilized around the world.⁴³ One of the main
46
47 reasons is lack of enough rigorous evidence on the implementation of HIVST to
48
49 promote HIV testing, which will aggravate the concerns for potential hazards of
50
51 HIVST without supervision.⁴¹
52
53
54
55
56
57
58
59
60

1
2
3
4 This study is designed to explore the effectiveness of free HIVST kits availability
5
6 on increasing HIV testing frequency among MSM in a resource-limited country, as
7
8 previous RCTs have been performed only in developed countries.^{24 25} Several types of
9
10 HIVST kits have been approved by China's regulation department.³⁷ However, there
11
12 are no relevant policies for use and regulation of the self-testing kits. China is
13
14 exploring strategic approaches to integrate HIVST with site-based HIV testing
15
16 services. This RCT study targets both recent testers and non-recent testers and HIV
17
18 testing frequencies for the latter group are far below the recommended level. If
19
20 successful, the study will provide evidence for policymakers to scale up the HIVST
21
22 approach to reach more high-risk individuals. The evidence from this study could also
23
24 be utilized to develop tailored and contextualized HIV prevention strategies for
25
26 Chinese MSM.
27
28
29
30
31
32

33 A major innovation of this study is to determine the effects of distribution of
34
35 HIVST kits from MSM to their sexual partners on enlarging HIV testing coverage.
36
37 HIV-positive MSM who were infected through regular or casual sexual partners
38
39 accounted for an increasing proportion of newly infected individuals.²³ Although
40
41 partner testing (encouraging MSM to bring their partners to have HIV tests) has been
42
43 recommended by WHO since 2012,⁴⁴ few data are available to assess the
44
45 implementation of this policy.⁴⁵ The approach of self-testing has the potential to
46
47 improve partner testing for HIV due to its convenience and privacy. However, to our
48
49 best knowledge, there is no study reporting the effectiveness for partner testing with
50
51 distribution of free HIVST kits among MSM in China. Evidence from this study will
52
53
54
55
56
57
58
59
60

1
2
3 help to guide the application of HIVST kits to promote partner testing and scale up
4
5
6 HIV testing coverage.
7

8
9 The major challenge of this study is to maintain our participants for 12 months.
10
11 Previous longitudinal studies reported about 18% of participants lost to follow up
12
13 among MSM in China.^{46 47} To tackle this problem, we will enlarge the sample size by
14
15 20%, and contact participants every 3 months by asking them to fill out the follow-up
16
17 questionnaires. Moreover, data from the sequenced follow-up evaluations could
18
19 demonstrate dynamic changes in HIV testing frequency, and high-risk sexual behavior,
20
21 which may expand understanding about implementation of HIVST among MSM and
22
23 their sexual partners.
24
25
26
27
28

29 This study has several limitations. First, participants must have a rapid HIV test
30
31 (only HIV negative individuals will be enrolled) at recruitment settings prior to
32
33 entering the study, which will exclude some MSM who live far from study settings or
34
35 are concerned about stigma. Second, free HIVST kits will be provided, and thus the
36
37 result cannot be generalized directly to the community, where HIVST kits are not free
38
39 or may be expensive. Third, finger-prick based testing kits will be used, so the results
40
41 may not apply to oral-fluid based kits. A fourth limitation is that data about sexual
42
43 partners' use of HIVST kits will be obtained indirectly by report of MSM without
44
45 direct verification.
46
47
48
49
50

51 **Author affiliations**

52
53
54
55 1 Xiangya Nursing School of Central South University, Changsha, Hunan, China
56
57

1
2
3 2 UCLA School of Nursing, Los Angeles, California, USA
4
5

6 3 NYU College of Nursing, New York, USA
7
8

9 **Acknowledgements**

10
11
12 We thank the staff in Zuo An Cai Hong (the gay-friendly CBO) for their assistance in
13
14 recruitment for this study.
15
16

17 **Contributors**

18
19
20 CZ and XL initiated and designed this protocol, with DK and LG providing expertise
21
22 on the methodology of the study. CZ, XL and JZ helped with the design of the
23
24 questionnaires. All authors edited the protocol and agreed with the final manuscript.
25
26
27

28 **Funding**

29
30
31 This study was supported by Central South University Graduate Independent
32
33 Exploration Innovation project (2018zzts885), Central South University
34
35 Innovation-driven project (2018CX036) and Fogarty International (D43 TW009579).
36
37
38

39 **Competing interests**

40
41
42 The authors declare that they have no competing interests.
43
44
45

46 **Abbreviations**

47
48
49 MSM: men who have sex with men; HIVST: HIV self-testing; CDC: Center for
50
51 Disease Prevention and Control; RCT: randomised controlled trial; CBO: community
52
53 based organization; RA: research assistant.
54
55
56

References

1. World Health Organization. Global Health Observatory (GHO) data. Geneva, Switzerland: WHO, 2017.
2. UNAIDS. AIDS by the numbers: AIDS is not over, but it can be. Geneva, Switzerland: UNAIDS, 2016.
3. UNAIDS. The global HIV/AIDS epidemic. Geneva, Switzerland: UNAIDS, 2017.
4. The Chinese Center for Disease Control and Prevention. Important fact about HIV/AIDS. 2014.
http://www.chinacdc.cn/jkzt/crb/zt/azb/zstd/201412/t20141201_107282.html
(accessed 9 March 2018).
5. Qin Q, Tang W, Ge L, et al. Changing trend of HIV, syphilis and hepatitis C among men who have sex with men in China. *Sci Rep* 2016;6:31081.
6. Tang S, Tang W, Meyers K, et al. HIV epidemiology and responses among men who have sex with men and transgender individuals in China: a scoping review. *BMC Infect Dis* 2016;16:588.
7. The Chinese Center for Disease Control and Prevention. Update on the AIDS/STDS epidemic in China in December 2017. 2017.
[http://kns.cnki.net/KCMS/detail/11.4818.R.20180207.1451.001.html?uid=WEEvREc-wSIJHSldRa1FhcEE0RVZxejRjRktOVSSyZjZoc2Z5YXZqUW01UT0=\\$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4ggI8Fm4gTkoUKaID8j8gFw!!&v=MDY2MDJuTXJ](http://kns.cnki.net/KCMS/detail/11.4818.R.20180207.1451.001.html?uid=WEEvREc-wSIJHSldRa1FhcEE0RVZxejRjRktOVSSyZjZoc2Z5YXZqUW01UT0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4ggI8Fm4gTkoUKaID8j8gFw!!&v=MDY2MDJuTXJ)

[ZOUNaT3NQWXc5TXptUm42ajU3VDNmbHFXTTBDTEw3UjdxZWIrWnNGeXpsVTc3TEIGND1QUy9TYjdHNEg5](https://doi.org/10.1136/bmjopen-2018-024423) (accessed 9 March 2018).

8. UNAIDS. Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland: UNAIDS, 2014.

9. Zou H, Hu N, Xin Q, et al. HIV testing among men who have sex with men in China: a systematic review and meta-analysis. *AIDS Behav* 2012;16:1717-28.

10. Zou H, Wu Z, Yu J, et al. Sexual risk behaviors and HIV infection among men who have sex with men who use the internet in Beijing and Urumqi, China. *J Acquir Immune Defic Syndr* 2010;53(Suppl 1):S81-7.

11. Wang HY, Xu JJ, Zou HC, et al. Sexual risk behaviors and HIV infection among men who have sex with men and women in China: evidence from a systematic review and meta-analysis. *BioMed Res Int* 2015;2015:850132.

12. Valdiserri RO. Late HIV diagnosis: bad medicine and worse public health. *PLoS Med* 2007;4(6):e200.

13. World Health Organization. Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. Geneva, Switzerland: WHO, 2016.

14. Pant Pai N, Sharma J, Shivkumar S, et al. Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a systematic review. *PLoS Med* 2013;10:e1001414.

- 1
2
3
4 15. Frye V, Wilton L, Hirshfeld S, et al. "Just because it's out there, people aren't
5
6 going to use it." HIV self-testing among young, black MSM, and transgender women.
7
8 AIDS Patient Care STDS 2015;29:617-24.
9
10
11 16. Bilardi J E, Walker S, Read T, et al. Gay and bisexual men's views on rapid
12
13 self-testing for HIV. AIDS Behav 2013;17:2093-9.
14
15
16 17. UNAIDS. The gap report [EB/OL]. Geneva, Switzerland: UNAIDS, 2015.
17
18
19
20 18. Figueroa C, Johnson C, Verster A, et al. Attitudes and acceptability on HIV
21
22 self-testing among key populations: a literature review. AIDS Behav 2015;19:
23
24 1949-65.
25
26
27 19. Greacen T, Friboulet D, Fugon L, et al. Access to and use of unauthorised online
28
29 HIV self-tests by internet-using French-speaking men who have sex with men. Sex
30
31 Transm Infect 2012;88:368-74.
32
33
34 20. Wong HT, Tam HY, Chan DP, et al. Usage and acceptability of HIV self-testing in
35
36 men who have sex with men in Hong Kong. AIDS Behav 2015;19:505-15.
37
38
39 21. Huang E, Marlin RW, Young SD, et al. Using Grindr, a smartphone
40
41 social-networking application, to increase HIV self-testing among Black and Latino
42
43 men who have sex with men in Los Angeles, 2014. AIDS Educ Prev 2016;28:341-50.
44
45
46 22. Wei C, Yan H, Yang C, et al. Accessing HIV testing and treatment among men
47
48 who have sex with men in China: a qualitative study. AIDS Care 2014;26:372-8.
49
50
51 23. UNAIDS. UNAIDS Data 2017. Geneva, Switzerland : UNAIDS, 2017.
52
53
54
55
56
57
58
59
60

1
2
3
4 24. Katz D, Golden M, Hughes J, et al. HIV self-testing increases HIV testing
5
6 frequency among high-risk men who have sex with men: a randomized controlled trial
7
8 [abstract]. Vancouver, Canada: 8th International AIDS Society Conference, 2015.
9

10
11 25. Jamil MS, Prestage G, Fairley CK, et al. Effect of availability of HIV self-testing
12
13 on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH):
14
15 a waiting-list randomised controlled trial. *Lancet HIV* 2017;4:e241-e250.
16
17

18
19 26. Sharma A, Chavez P R, Macgowan R J, et al. Willingness to distribute free rapid
20
21 home HIV test kits and to test with social or sexual network associates among men
22
23 who have sex with men in the United States. *AIDS Care* 2017;29:1499-1503.
24
25

26
27 27. Lv LF. HIV incidence and using of oral rapid test kits for regular male sexual
28
29 partner among men who have sex with men in Beijing. Hebei Medical University,
30

31
32 2017. <http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD>
33
34
35 [201801&filename=1017826881.nh&uid=WEEvREcwSIJHSlDRa1FhdXNXa0hHRXZ](http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD)
36
37 [iaHBoWVJieWNUcEdpajJMVaWMD0=\\$9A4hF_YAuvQ5obgVAqNKPCYcEjKens](http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD)
38
39 [W4ggI8Fm4gTkoUKaID8j8gFw!!&v=MzAyODhaT1pwRkNqbFZMek1WRjI2R2Jl](http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD)
40
41 [NkdObkVycEViUEISOGVYMUx1eFITN0RoMVQzcVRyV00xRnJDVVJMS2Y=](http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD) _
42
43

44
45 (accessed 9 March 2018).
46

47
48 28. Harsha T, Samuel HM, Sue NM, et al. Promoting male partner testing and safer
49
50 sexual decision-making through secondary distribution of HIV self-tests by
51
52 HIV-uninfected female sex workers and women receiving antenatal and postpartum
53
54 care in Kenya: a cohort study. *Lancet HIV* 2016;3: e266-74.
55
56
57

- 1
2
3
4 29. Ministry of Health of the People's Republic of China. 2016 China AIDS response
5
6 progress report. 2016.
7
8 [http://hunan.sina.com.cn/news/2016-11-27/detail-ifxyawmp0324958.shtml?from=hun](http://hunan.sina.com.cn/news/2016-11-27/detail-ifxyawmp0324958.shtml?from=hunan_ydph)
9 [an_ydph](http://hunan.sina.com.cn/news/2016-11-27/detail-ifxyawmp0324958.shtml?from=hunan_ydph) (accessed 9 March 2018).
10
11
12
13
14 30. HIV epidemic in Hunan Province at the end of October 2016 (in Chinese).
15
16 http://www.eol.cn/hunan/hunannews/201611/t20161128_1471024.shtml (accessed 9
17 March 2018).
18
19
20
21
22 31. Huang ZL, Shan F, Yan RL. Analysis of HIV/AIDS high risk behavior and influencing
23 factors among men who have sex with men in Changsha. *Practical Preventive Med*
24 2013;20:1435-8.
25
26
27
28
29
30 32. Patel RR, Patel S, Clarke E, et al. Guidance and practice on frequency of HIV and
31 sexually transmitted infection testing in men who have sex with men - what is the
32 European situation? *Int J STD AIDS* 2014;25:213-8.
33
34
35
36
37
38 33. Templeton DJ, Read P, Varma R, et al. Australian sexually transmissible infection
39 and HIV testing guidelines for asymptomatic men who have sex with men 2014: a
40 review of the evidence. *Sex Health* 2014;11:217-29.
41
42
43
44
45
46 34. Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of oral kits for
47 HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in
48 Blantyre, Malawi. *PLoS Med* 2011;8:e1001102.
49
50
51
52
53
54 35. Li YF, Wang YM, Zhang RR, et al. Analysis on accuracy and influencing factors
55 of oral fluid-based rapid HIV self-testing among men who have sex with men.
56
57
58
59
60

- Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2016;37:72-5.
36. Hurt CB, Powers KA. Self-testing for HIV and its impact on public health. *Sex Transm Dis* 2014;41:10-2.
37. Yan L, Xiao P, Yan H, et al. The advance of detection technology of HIV self-testing. *Chin J Prev Med* 2017;51:1053-6.
38. Alere. Alere determine HIV-1/2 quick reference card-global (English).
<https://www.alere.com/zh/zh/product-details/determine-hiv-1-2.html>. (accessed 9 March 2018).
39. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 2007;39:175-191.
40. Zhong F, Tang W, Cheng W, et al. Acceptability and feasibility of a social entrepreneurship testing model to promote HIV self-testing and linkage to care among men who have sex with men. *HIV Med* 2016;18:376-382.
41. Alere. Alere determine HIV-1/2 brochure-global (English).
<https://www.alere.com/zh/zh/product-details/determine-hiv-1-2.html>. (accessed 9 March 2018)
42. Zhang C, Li X, Brecht M L, et al. Can self-testing increase HIV testing among men who have sex with men: A systematic review and meta-analysis. *PLoS One* 2017;12:e0188890.

- 1
2
3
4 43. Campbell S, Klein R. Home testing to detect human immunodeficiency virus:
5
6 boon or bane? *J Clin Microbiol* 2006;44:3473-6.
7
8
9 44. World Health Organization. Guidance on couples HIV testing and counselling -
10
11 including antiretroviral therapy for treatment and prevention in serodiscordant couples:
12
13 recommendations for a public health approach. Geneva, Switzerland: WHO, 2012.
14
15
16 45. World Health Organization. Global health sector response to HIV, 2000-2015:
17
18 focus on innovations in Africa: progress report. Geneva, Switzerland: WHO, 2015.
19
20
21 46. Yan HJ, Yang HT, Zhao JK et al. Long-chain peer referral of men who have sex
22
23 with men: a novel approach to establish and maintain a cohort to measure HIV
24
25 incidence, Nanjing, China. *J Acquir Immune Defic Syndr* 2012;2:177-84.
26
27
28 47. Chen J, Li XH, Xiong Y, et al. Reducing the risk of HIV transmission among men
29
30 who have sex with men: a feasibility study of the motivational interviewing
31
32 counseling method. *Nurs Health Sci* 2016;18:400-7.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure1 Flow of recruitment and intervention.

117x147mm (300 x 300 DPI)

BMJ Open

Effectiveness of Self-testing Kits Availability on Improving HIV Testing Frequency for Chinese Men Who Have Sex with Men and Their Sexual Partners: A Protocol for A Multicenter Randomised Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024423.R1
Article Type:	Protocol
Date Submitted by the Author:	29-Aug-2018
Complete List of Authors:	Zhang, Ci; Central South University Xiangya School of Nursing, Li, Xianhong; Central South University Xiangya School of Nursing, Koniak-Griffin, Deborah; School of Nursing of University of California at Los Angeles Goldsamt, Lloyd; New York University Rory Meyers College of Nursing Zhou, Jing; Central South University Xiangya School of Nursing
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Diagnostics
Keywords:	HIV, men who have sex with men (MSM), HIV self-testing (HIVST), sexual partner testing, HIV testing frequency

SCHOLARONE™
Manuscripts

Running title: A RCT STUDY ON HIV SELF-TESTING EFFECTIVENESS

**Effectiveness of Self-testing Kits Availability on Improving HIV Testing
Frequency for Chinese Men Who Have Sex with Men and Their Sexual Partners:
A Protocol for A Multicenter Randomised Controlled Trial**

Ci Zhang¹, Xianhong Li^{1*}, Deborah Koniak-Griffin², Lloyd A. Goldsamt³, Jing Zhou¹

1 Xiangya Nursing School of Central South University, Changsha, China

2 School of Nursing of University of California at Los Angeles, Los Angeles, USA

3 New York University Rory Meyers College of Nursing, New York, USA

*Corresponding author: 172 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China;

xianhong_li228@hotmail.com; +86 0731-82650264 (Xianhong Li)

Word count: 4158

Abstract

Introduction: HIV epidemic is increasing among men who have sex with men (MSM) in China, yet HIV testing uptake remains low. As an emerging approach, HIV self-testing (HIVST) has the potential to promote HIV testing coverage and frequency in this population. However, evidence of the effectiveness on implementation of HIVST among Chinese MSM and their sexual partners is scarce.

Methods and analysis: The randomized controlled trial will be performed in Changsha, Changde, Shaoyang, and Yiyang, Hunan province, China, recruiting 184 recent testers (men who had at least one HIV test within the past 2 years) and 26 non-recent testers (men who did not have HIV tests within 2 years or never had an HIV test). Eligible men will be randomly divided 1:1 into two groups: intervention (with free HIVST kits plus site-based HIV testing services) and control (site-based HIV testing services only). Participants in the intervention group will be provided with two free finger-prick-based HIVST kits, and can apply for two to four kits every 3 months for 1 year.

Participants in both groups will complete questionnaires via WeChat at five separate times: baseline, 3rd, 6th, 9th, and 12th month. The primary outcome is the mean number of HIV tests for MSM over the 12-month study period. The secondary outcome is the mean number of HIV tests for sexual partners of MSM over the 12-month study period. The tertiary outcomes are the self-reported proportion of consistent condom usage for anal sex, and the numbers of sexual partners during the

12-month study period.

Ethics and dissemination: The study has been approved by the Institutional Review Board of Behavioral and Nursing Research in Xiangya School of Nursing of Central South University, China (2018002). Study results will be disseminated through conferences and academic journals.

Trial registration number: Chinese Clinical Trial Registry (ChiCTR1800015584).

Strengths and limitations of this study

- No study has reported effectiveness of free HIV self-testing (HIVST) kits availability on increasing HIV testing frequency among men who have sex with men (MSM) in China.
- One major innovation of this study is to determine effectiveness of distribution of HIVST kits from MSM to their sexual partners, which will provide evidence to guide the application of HIVST to promote partner testing and improve HIV testing coverage.
- Findings from this study will have potential to help policymakers to scale up the HIVST approach to reach more high-risk individuals and could be utilized to develop contextualized HIV prevention strategies for Chinese MSM.
- In this longitudinal study, maintaining MSM for 12 months is difficult and thus loss to follow-up is possible.
- Data about sexual partners' use of HIVST kits which will be obtained indirectly

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

by report of MSM may be inclined to bias.

Introduction

Globally, HIV remains a major public health threat, with a total of approximately 36.7 million individuals infected at the end of 2015.¹ Despite great efforts to improve HIV prevention and treatment, the annual number of newly HIV-infected individuals remains around 2.2 million over the past 5 years.² Notably, the transmission rate of HIV among men who have sex with men (MSM) is alarmingly high globally, accounting for 30% of all infected individuals.³ China has also faced a severe HIV epidemic among MSM,⁴ with the HIV prevalence among MSM increasing nearly 9 times from 0.9% in 2003 to 8.0% in 2015,^{5 6} and 25.5 % of new infections were attributed to MSM in 2017.⁷

In 2014, UNAIDS set up the "90-90-90" goal aiming to control the HIV epidemic by 2020, with 90% of HIV-infected individuals getting tested and diagnosed, 90% of diagnosed individuals receiving treatment, and 90% of individuals under treatment achieving viral suppression.⁸ However, only 60% of HIV-positive individuals have been tested around the world,³ far from reaching the first goal. The situation in China is similar. A recent meta-analysis showed that 62% of MSM had not taken an HIV test over the past 12 months, and nearly 50% had never been tested in their lifetime.⁹ Lack of adequate HIV testing services, multiple sexual partners, and frequent high-risk sexual behaviors have exacerbated HIV prevalence among MSM and may lead to further transmission to the general population via sexual contacts with female sexual

1
2
3 partners.^{10 11} Moreover, delayed HIV testing and delayed antiretroviral treatment may
4
5 increase the probability of HIV/AIDS-related deaths.¹² Thus, it is essential to promote
6
7 HIV testing, especially among MSM.
8
9

10
11 As a complementary approach, HIV self-testing (HIVST) has significant potential
12
13 to scale up HIV testing coverage. It can be used by individuals to collect specimens
14
15 (their own blood or saliva), perform a test, and read the test results by themselves.¹³
16
17 With the characteristics of convenience, privacy, and confidentiality,¹⁴⁻¹⁶ HIVST may
18
19 be very attractive to MSM who are impacted by HIV/AIDS-related stigma and
20
21 discrimination; limited transportation; and/or reluctance to wait when taking the test
22
23 at the traditional sites, such as the Center for Disease Prevention and Control [CDC],
24
25 sites of voluntary counseling and testing services for AIDS, and hospitals.¹⁷ A recent
26
27 review indicated that HIVST kits had high acceptability (>67%) among MSM of the
28
29 14 included studies,¹⁸ not specific to oral fluid based or blood based. However, the
30
31 usage rate of HIVST kits among MSM was low in certain countries, with reported
32
33 rates of 3.5% in France, 6.1% in China, and 11.6% in the USA.¹⁹⁻²¹ The barriers to use
34
35 included worry about a positive result, the relatively high cost of kits, and concerns
36
37 about correct usage of the kits.²²
38
39
40
41
42
43
44
45

46
47 Data released by UNAIDS (2017) underlines that reaching MSM and their
48
49 partners with HIV testing services may have the potential to control the HIV
50
51 epidemic.²³ In the United States, a randomized controlled trial (RCT) showed that the
52
53 availability of HIVST could increase HIV testing uptake among MSM.²⁴ A previous
54
55 RCT in Australia also indicated that HIVST could increase the HIV testing frequency
56
57
58
59
60

1
2
3 among MSM, especially in delayed testers (those who had never received HIV testing
4 or had not been tested within 2 years).²⁵ Moreover, a previous US study showed that
5
6 79%-91% of MSM were willing to distribute HIVST kits to their sexual partners.²⁶
7
8 Serostatus disclosure to their regular or casual sexual partners after testing with
9
10 HIVST kits would promote safe sexual practices if the testing results were
11
12 positive.^{27 28} Thus, distribution of HIVST kits from MSM to their sexual partners
13
14 could be an effective way to expand HIV testing and reduce high-risk sexual
15
16 behaviors among MSM.^{27 28}

17
18
19 In accordance with this strategy, a guideline on HIVST was issued by the WHO
20
21 in 2016 to promote HIV testing and partner disclosure.¹³ However, in the guideline,
22
23 there was only evidence from two RCTs to support the effectiveness of HIVST kits
24
25 for improving HIV testing frequency among MSM.^{24 25} Further research is urgently
26
27 needed to determine the effects of providing free HIVST kits to MSM and their sexual
28
29 partners in China.

30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Methods

Study objectives

This randomized controlled trial is designed to determine whether the distribution of HIVST in an intervention group compared to a control group improves the frequency of HIV testing among MSM (primary aim) and their sexual partners (male and female) (secondary aim). The study also aims to explore whether HIVST reduces high risk sexual behaviors of MSM (tertiary aim). Outcomes will be compared

1
2
3 between participants in the intervention and control groups who have histories of
4
5 recent and non-recent HIV testing.
6
7

8 9 **Study settings**

10
11 This study will be conducted in four cities within Hunan Province, namely
12 Changsha (the capital of the province), Changde, Shaoyang, and Yiyang. The settings
13 include urban and rural areas. Delivery services of free HIVST kits are unavailable
14 through any organizations in these cities. HIV prevalence in Hunan Province ranks 9th
15 nationally in mainland China.²⁹ The number of HIV/AIDS patients in Hunan Province
16 was about 24,000 in 2016, with 4,974 newly infected.³⁰ Notably, 64.8% of the new
17 patients were infected through male-to-male sexual intercourse.³⁰ In our unpublished
18 cross-sectional study, 37.7% of MSM had never tested for HIV in Hunan Province.
19
20
21
22
23
24
25
26
27
28
29
30

31 32 **Participants**

33
34 Two subgroups of MSM will be recruited: recent testers (men who had at least
35 one HIV test within the last 2 years) and non-recent testers (men who did not have
36 HIV tests within the last 2 years or never had a HIV test). Zuo An Cai Hong, a
37 gay-friendly community-based organization (CBO) ---- with seven sub-locations in
38 the participating settings of Hunan Province, will collaborate in this study. The CBO
39 provides rapid HIV tests, counseling, and referral for MSM, and it conducts around
40 1,500-2,000 HIV tests each year. Thus, the feasibility of the study recruitment is
41 supported.
42
43
44
45
46
47
48
49
50
51
52
53
54

55 56 **Inclusion criteria**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Individuals are eligible for participation if they meet the following criteria: (1) born as a male; (2) 18 years of age or older; (3) reporting condomless anal or oral sex with men in the past 3 months; (4) HIV negative by rapid HIV testing at screening; (5) planning to reside in Hunan Province during the next year; (6) possessing a smartphone and adept in using WeChat; and (7) voluntarily agreeing to participate in the study and provide written informed consent.

Exclusion criteria

Individuals will be excluded if they: (1) are participating in other research programs (2) cannot speak and/or read Chinese, or (3) score higher than 35 on the Brief Psychiatric Rating Scale.³¹

Study procedure

Study design

A multisite RCT design will be used to determine the effectiveness of HIVST on improving HIV testing frequency among Chinese MSM and their sexual partners, and to explore whether HIVST reduces high risk sexual behaviors of MSM in China. Participants will be randomly assigned to intervention and control groups, with a 1:1 ratio (by CZ). The intervention group will be provided with free HIV self-testing kits and site-based HIV testing services for 1 year, and participants in the control group will have access to site-based HIV testing for 1 year (the control group will also receive the HIVST kits after the study concludes) (Fig. 1).

Recruitment

1
2
3
4 Participants will be recruited starting from December 2017 through posting of
5
6 flyers (1) in the office and waiting areas of the four study locations, and (2) on Blued
7
8 (a social media site for MSM), the instant online-chatting platform of QQ and WeChat
9
10 (public number of Zuo An Cai Hong). CBO staff also will provide study information
11
12 to MSM who are coming for testing or counseling. A WeChat account and a phone
13
14 number will be established solely for study online consultation and follow-up.
15
16
17

18
19 MSM who express interest in this study will be contacted by the research
20
21 assistant (RA) (CZ) via WeChat or cellphone for purposes of scheduling an
22
23 appointment at the nearby sublocation of the CBO to complete the screening
24
25 procedure and receive a rapid HIV test following oral consents. Fig.1 presents the
26
27 recruitment flow chart.
28
29
30
31
32
33
34

35 Figure1 Flow of recruitment and intervention.
36
37

38 **Randomization**

39
40
41 Securing of written informed consent will be obtained from eligible MSM prior
42
43 to randomization into the intervention group and control group. Computer-generated
44
45 randomized number tables developed by SPSS 18.0 (by JZ) will be used for this
46
47 purpose. Two separate randomized number tables will be used for recent testers and
48
49 non-recent testers.
50
51
52

53 **Blinding**

54
55
56
57
58
59
60

1
2
3
4 During the screening and informed consent procedure, the RAs will be blinded to
5
6 the randomization number tables, which will be sealed in opaque and sequentially
7
8 numbered envelopes. After screening procedure and written informed consent, the
9
10 envelope will be opened and the group assignment will be exposed to both the
11
12 participants and the RAs. Throughout the project, the data analysts will be blinded to
13
14 code numbers representing the group assignments.
15
16

17 18 **Intervention group** 19

20
21
22 Participants in the intervention group will have access to free HIVST kits in
23
24 addition to site-based HIV testing services. They will be encouraged to perform HIV
25
26 tests for themselves and their sexual partners using the HIVST kits. At enrollment,
27
28 participants will be provided two HIVST kits along with detailed instructions and
29
30 information without any face-to-face training from our study. Instructions and
31
32 additional information will also be posted in the official account of Zuo An Cai Hong
33
34 on WeChat (<https://mp.weixin.qq.com/s/vi9Nl-uLOeWnoJajvsq63Q>). Participants in
35
36 the intervention group will be asked to submit a photo of each test result, following
37
38 which they can apply to receive new kits. A cross-sectional study in China indicated
39
40 that the mean number of sexual partners of MSM was 4.79 during the past 6 months.³²
41
42 Given the repeated tests, distribution to sexual partners and the recommendation of
43
44 2-4 tests per year for high-risk MSM,^{33 34} participants can apply for 2-4 kits every 3
45
46 months, and a maximum of 12 kits for 1 year. For participants' convenience, these kits
47
48 can be obtained at study sites or through express delivery. With 24 hours' notice, the
49
50 kits will be delivered in private packages without any information about HIV/AIDS or
51
52
53
54
55
56
57
58
59
60

1
2
3 testing visible on the packaging. To encourage MSM to send back the photos of their
4
5 results, participants will be charged a 30¥ (the equivalent of \$5 USD) deposit for each
6
7 kit, which will be returned immediately after the RA receives the result photos. Each
8
9 kit will be numbered sequentially on the outer packing before distribution for
10
11 monitoring purposes. In addition, MSM can also purchase HIVST kits online if they
12
13 need more than 4 kits every 3 months.
14
15
16
17

18 **The product of self-testing kits**

19
20 Selection of the type of HIVST kits (oral fluids from mouth swabs versus blood
21
22 samples from finger pricking) was made with consideration of research findings.
23
24 Previous studies indicate that 5%-10% of participants made procedural errors,^{35 36} and
25
26 10% requested additional help beyond the provided demonstration and instructions
27
28 when using oral self-testing kits.³⁶ Thus, a finger-prick based HIVST kit, a third
29
30 generation of Alere Determine HIV 1/2 rapid assay (Alere Medical Co., Ltd, Japan),
31
32 approved by the US Food and Drug Administration and China's State Food and Drug
33
34 Administration was selected for use in this study.^{37 38} This test can detect HIV 1/2
35
36 antibodies in blood specimens at six weeks post-infection.³ The specimen is obtained
37
38 by pricking a finger using a disposable peripheral blood needle made by
39
40 STERiLANCE in China. Blood is collected by EDTA capillary tube and dropped on a
41
42 specimen reaction zone of the HIVST kit, and then Alere Determine Chase solution is
43
44 added in the reaction zone.³⁹ The result can be read in 15-60 minutes.³⁹ The
45
46 specificity and sensitivity of the Alere Determine HIV 1/2 are 99.68% and 100%,
47
48 respectively.⁴⁰ Every kit is accompanied by instructions including testing procedure,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 interpretation of results, and notes. The HIVST is preliminary for screening, and a
4
5 positive result requires confirmation by enzyme-linked immunoassay in the CDC
6
7 laboratory.
8
9

10 11 **Support hot lines**

12
13
14 Participants will be able to contact RAs by WeChat or a 24-h telephone support
15
16 line to obtain consultation on the HIVST administration and interpretation of results.
17
18 Records will be maintained on the purpose of the consultation.
19
20

21 22 **Control group**

23
24
25 Participants in the control group will receive the usual care provided at the CDC,
26
27 CBO-based rapid HIV testing sites, or local hospitals where they may receive HIV
28
29 testing. Also, they can buy HIVST kits online if needed. After completion of the
30
31 12-month follow-up, these participants can obtain a free supply of HIVST kits for a
32
33 12-month period. The same procedure offered to the intervention group will be
34
35 implemented for the control group after follow-up evaluations are completed.
36
37
38
39

40 41 **Follow-up of positive results**

42
43
44 Participants who have positive results for themselves or their sexual partners
45
46 using HIVST kits will be advised to contact the RAs by the 24-h telephone hotline or
47
48 WeChat. The RAs will provide additional consultation about the testing results and
49
50 recommend them to have confirmatory laboratory tests in local CDC. Transfer
51
52 services to the local CDC and professional psychological counselling institute will be
53
54 provided, as necessary. If the participants are confirmed to be HIV positive, the
55
56
57
58
59

process of follow-up data collection will be discontinued for them.

Outcome measures

The primary outcome is the mean number of HIV tests used by MSM from baseline to the 12-month evaluation. This number will be calculated based upon the total number of HIVST kits and site-based HIV tests reported by participants. The secondary outcome is the mean number of HIV tests for sexual partners within 12 months reported by MSM, using the same calculations. The tertiary outcomes are the frequency of consistent condom usage for anal sex (never/sometimes/usually/always using condoms), and the numbers of reported sexual partners during the past 12 months.

Data collection

Data will be collected anonymously through online questionnaires produced by “sojump” (<http://www.sojump.com>), a professional online survey company, which has a confidential contract with the study team to encrypt the data and ensure the safety and privacy of the participants’ information. An account with *sojump* will be set up, and the password will only be accessed by the RAs. Participants in the intervention and control groups will receive and complete the questionnaires via WeChat five times, at baseline and 3-, 6-, 9-, and 12-month follow-ups.

The content validity of the baseline questionnaire was obtained by expert review (including two experts from CDC, two experts on clinical psychology and one expert on HIV/AIDS prevention and control). Included in this questionnaire are items related

1
2
3
4 to social-demographic information, HIV testing history (number of HIV tests, test
5
6 results, and reasons for site-based HIV tests/self tests), partner testing history (number
7
8 of tests with HIVST kits distributed by MSM and site-based HIV tests recommended
9
10 by MSM, test results, and number of sexual partners' refusing to test), and high-risk
11
12 sexual behavior history (number of sexual partners, number of and reasons for
13
14 condomless oral or anal sex), during the past year and last 3 months. Two previously
15
16 pilot-tested items assess HIV testing self-efficacy (Cronbach's $\alpha = 0.74$) with
17
18 statements about confidence in HIV self-testing and confidence in regular HIV testing
19
20 (every 6 months). Response choices are based on a 10-point Likert-type scale ranging
21
22 from 1 = not at all confident to 10 = completely confident.
23
24
25
26
27

28 The follow-up questionnaires, to be administered at 3-month intervals, include
29
30 items from the baseline measure evaluating HIV testing, partner testing, high-risk
31
32 sexual behavior during the past 3 months, and self-efficacy for HIV testing. In
33
34 addition, data will be collected from men in both groups about the sources of
35
36 obtaining HIV self-test kits, such as from our study, online purchase or their friends.
37
38 Participants who report positive or uncertain results on HIVST will be asked whether
39
40 they have linked to care for confirmatory laboratory HIV test and antiretroviral
41
42 treatment.
43
44
45
46
47

48 At the 12-month follow-up, participants will also be asked questions about their
49
50 experiences with self-testing and their willingness to use HIVST kits in the future.
51
52 Compensation (\$16 per person) will be provided to participants for their time spent
53
54 after filling out the questionnaires each time.
55
56
57
58
59
60

1
2
3 If any follow-up questionnaires are not been completed, we will remind
4 participants via WeChat and/or text messages three times at intervals of 1, 2, and 3
5
6
7
8 weeks after the questionnaires being sent.
9

10 11 **Statistical analysis plan**

12 13 **Analysis plan**

14
15
16
17 Analyses will be conducted using SPSS 18.0. Data will be imported directly to
18 SPSS18.0 from *sojump*, avoiding data inputting errors. Statistical results will be
19 reported with *p* values and 95% *CI* for the corresponding hypothesis tests. *P* values
20 <0.05 are considered statistically significant. Baseline characteristics of the two
21 groups will be compared. Analyses will be performed between the intervention and
22 control groups for recent and non-recent testers.
23
24
25
26
27
28
29
30
31

32
33 The primary analysis will compare the mean number of HIV tests within 12
34 months by using independent sample *t*-tests. At the end of the study, generalized
35 estimated equation models will be used to analyze the variation tendency of the mean
36 number of HIV tests every 3 months for participants. We will also use independent
37 sample *t*-tests to analyze the mean number of HIV tests for sexual partners of MSM.
38
39
40
41
42
43
44

45
46 The frequency of high-risk sexual behaviors every 3 months will be analyzed
47 using a generalized estimated equation model. The relationship between the results of
48 HIVST (positive, negative or uncertain) and condom use rate after the test will be
49 explored using logistic regression analysis. The trend of HIV testing self-efficacy will
50 be explored with generalized estimated equation models. The rate of positive
51
52
53
54
55
56
57

1
2
3 self-testing results and the linkage to care (the rate of MSM who have confirmatory
4 laboratory testing and initiate antiretroviral treatment in CDC) will be analyzed
5
6 descriptively.
7
8
9

10 11 **Sample size**

12
13
14 The target sample size was calculated using G-power 3.0⁴¹ with a one-tailed test,
15 80% power, and a 5% significance level. Calculations of sample size were made with
16 consideration of previous research findings in China⁴² indicating the mean number of
17 HIV tests for recent testers was 1.35 tests per year. Guidelines recommend individuals
18 at high-risk have 2-4 HIV tests per year,^{33 34} thus an increase from 1.35 to 2 tests per
19 year [standard deviation: 1.61]⁴² is anticipated for recent testers. The mean number of
20 HIV tests for non-recent testers is 0.2 tests per year based upon findings of past
21 research in Australia.²⁵ Thus, we expect to detect an increase from 0.2 to 1 test per
22 year [standard deviation: 0.7]²⁵ for non-recent testers. Given a 20% missing rate, we
23 conservatively estimate 184 recent testers and 26 non-recent testers will help detect
24 the difference in HIV testing frequency between the two arms.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Study schedule**

43
44
45 Two years (December 14 2017 - December 13 2019) will be needed to complete
46 the study, including 6 months to recruit participants, 1 year for follow-up and
47 collecting data, and 6 months to process the data and report.
48
49
50
51
52

53 **Patient and public involvement**

54
55
56 We took participants' priorities into account by conducting interviews for 23
57

1
2
3
4 MSM to explore their experience and asking their preference for delivery
5
6 methods. Results from interviews indicated that 89.5% (17/19) MSM who had HIV
7
8 self-tests preferred finger-prick based testing kits, and all MSM expressed belief that
9
10 express mail was a great way to receive HIVST kits if no information about AIDS or
11
12 HIV showed on the package. This information helped us to design our study and
13
14 choose the appropriate delivery method. But these men were not involved in the study
15
16 design. In addition, they were not involved in the study recruitment and conduction
17
18 either. Potential participants have the right to refuse to participate in this study after
19
20 assessing the burden of the intervention (including long follow-up process and time
21
22 spent in completing questionnaires for five times). All participants will maintain rights
23
24 to access services at the CDC or CBO. After the study is completed, the results will be
25
26 disseminated to the study population.
27
28
29
30
31

32 33 **Ethics and dissemination** 34 35

36 The study has received an ethical approval from the Institutional Review Board
37
38 of Behavioral and Nursing Research in Xiangya School of Nursing of Central South
39
40 University, China (approval number 2018002). Moreover, the following measures will
41
42 be taken to meet ethical standards: (1) oral informed consent for rapid HIV testing at
43
44 the time of screening and written informed consent before enrollment will be required,
45
46 and (2) personal information of participants will be stored in an offline encrypted
47
48 computer that can only be accessed by the research team. Results from this study will
49
50 be disseminated through conferences and academic journals.
51
52
53
54
55
56
57
58
59
60

Trial registration

The study has been registered with Chinese Clinical Trial Registry [trial ID: ChiCTR1800015584, on April 9, 2018].

Discussion

The HIV epidemic is rapidly growing among MSM,³⁻⁵ yet HIV testing uptake remains far below the recommended level in China and other countries.^{3 9} Due to diverse socioeconomic status, the coverage of site-based HIV testing services differs by country and region. As a complementary approach, HIVST has the potential to expand availability of basic HIV testing services and broader HIV testing coverage.⁴³ However, HIVST has not been widely utilized around the world.⁴⁴ One of the main reasons is lack of enough rigorous evidence on the implementation of HIVST to promote HIV testing, which will aggravate the concerns for potential hazards of HIVST without supervision.⁴²

This study is designed to explore the effectiveness of free HIVST kits availability on increasing HIV testing frequency among MSM in a resource-limited country, as previous RCTs have been performed only in developed countries.^{24 25} Several types of HIVST kits have been approved by China's regulation department.³⁸ However, there are no relevant policies for use and regulation of the self-testing kits. China is exploring strategic approaches to integrate HIVST with site-based HIV testing services. This RCT study targets both recent testers and non-recent testers and HIV testing frequencies for the latter group are far below the recommended level. If

1
2
3
4 successful, the study will provide evidence for policymakers to scale up the HIVST
5
6 approach to reach more high-risk individuals. The evidence from this study could also
7
8 be utilized to develop tailored and contextualized HIV prevention strategies for
9
10 Chinese MSM.
11
12

13
14 A major innovation of this study is to determine the effects of distribution of
15
16 HIVST kits from MSM to their sexual partners on enlarging HIV testing coverage.
17
18 HIV-positive MSM who were infected through regular or casual sexual partners
19
20 accounted for an increasing proportion of newly infected individuals.²³ Although
21
22 partner testing (encouraging MSM to bring their partners to have HIV tests) has been
23
24 recommended by WHO since 2012,⁴⁵ few data are available to assess the
25
26 implementation of this policy.⁴⁶ The approach of self-testing has the potential to
27
28 improve partner testing for HIV due to its convenience and privacy. However, to our
29
30 best knowledge, there is no study reporting the effectiveness for partner testing with
31
32 distribution of free HIVST kits among MSM in China. Evidence from this study will
33
34 help to guide the application of HIVST kits to promote partner testing and scale up
35
36 HIV testing coverage.
37
38
39
40
41
42
43

44 The major challenge of this study is to maintain our participants for 12 months.
45
46 Previous longitudinal studies reported about 18% of participants lost to follow up
47
48 among MSM in China.^{47 48} To address this problem, we will enlarge the sample size
49
50 by 20%, and contact participants every 3 months by asking them to fill out the
51
52 follow-up questionnaires. Moreover, data from the sequenced follow-up evaluations
53
54 could demonstrate dynamic changes in HIV testing frequency, and high-risk sexual
55
56
57
58
59
60

1
2
3 behavior, which may expand understanding about implementation of HIVST among
4
5
6 MSM and their sexual partners.
7

8
9 This study has several limitations. First, participants must have a rapid HIV test
10 (only HIV negative individuals will be enrolled) at recruitment settings prior to
11 entering the study, which will exclude some MSM who live far from study settings or
12 are concerned about stigma. Second, free HIVST kits will be provided, and thus the
13 result cannot be generalized directly to the community, where HIVST kits are not free
14 or may be expensive. Third, finger-prick based testing kits will be used, so the results
15 may not apply to oral-fluid based kits. A fourth limitation is that data about sexual
16 partners' use of HIVST kits will be obtained indirectly by report of MSM without
17 direct verification. A final limitation is that the sample of non-recent testers is small
18 (n=26) which may limit generalizability for this group.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Author affiliations**

35
36
37 1 Xiangya Nursing School of Central South University, Changsha, Hunan, China
38

39
40 2 School of Nursing of University of California at Los Angeles, Los Angeles, USA
41

42
43 3 New York University Rory Meyers College of Nursing, New York, USA
44

45 **Acknowledgements**

46
47
48 We thank the staff in Zuo An Cai Hong (the gay-friendly CBO) for their assistance in
49 recruitment for this study.
50
51
52

53 **Contributors**

1
2
3 CZ and XL initiated and designed this protocol, with DK and LG providing expertise
4
5 on the methodology of the study. CZ and XL helped with the design of the
6
7 questionnaires. JZ provided the support of statistical analysis. All authors edited the
8
9 protocol and agreed with the final manuscript.
10
11
12

13 14 **Funding**

15
16
17 This study was supported by Central South University Graduate Independent
18
19 Exploration Innovation project (2018zzts885), Central South University
20
21 Innovation-driven project (2018CX036) and Fogarty International (D43 TW009579).
22
23

24 25 **Competing interests**

26
27
28 The authors declare that they have no competing interests.
29
30

31 32 **Abbreviations**

33
34 MSM: men who have sex with men; HIVST: HIV self-testing; CDC: Center for
35
36 Disease Prevention and Control; RCT: randomised controlled trial; CBO: community
37
38 based organization; RA: research assistant.
39
40

41 42 **References**

- 43
44
45 1. World Health Organization. Global Health Observatory (GHO) data. Geneva,
46
47 Switzerland: WHO, 2017.
48
49
50
51 2. UNAIDS. AIDS by the numbers: AIDS is not over, but it can be. Geneva,
52
53 Switzerland: UNAIDS, 2016.
54
55
56 3. UNAIDS. The global HIV/AIDS epidemic. Geneva, Switzerland: UNAIDS, 2017.
57
58
59

1
2
3
4 4. The Chinese Center for Disease Control and Prevention. Important fact about
5
6 HIV/AIDS. 2014.

7
8
9 http://www.chinacdc.cn/jkzt/crb/zt/azb/zstd/201412/t20141201_107282.html

10
11 (accessed 9 March 2018).

12
13
14 5. Qin Q, Tang W, Ge L, et al. Changing trend of HIV, syphilis and hepatitis C among
15
16 men who have sex with men in China. *Sci Rep* 2016;6:31081.

17
18
19 6. Tang S, Tang W, Meyers K, et al. HIV epidemiology and responses among men
20
21 who have sex with men and transgender individuals in China: a scoping review. *BMC*
22
23 *Infect Dis* 2016;16:588.

24
25
26
27
28 7. The Chinese Center for Disease Control and Prevention. Update on the
29
30 AIDS/STDS epidemic in China in December 2017. 2017.

31
32 <http://kns.cnki.net/KCMS/detail/11.4818.R.20180207.1451.001.html?uid=WEEvREc>

33
34 [wSIJHSldRa1FhcEE0RVZxejRjRktOVSSyZjZoc2Z5YXZqUW01UT0=\\$9A4hF_YAu](http://kns.cnki.net/KCMS/detail/11.4818.R.20180207.1451.001.html?uid=WEEvREc)

35
36 [vQ5obgVAqNKPCYcEjKensW4ggI8Fm4gTkoUKaID8j8gFw!!&v=MDY2MDJuTXJ](http://kns.cnki.net/KCMS/detail/11.4818.R.20180207.1451.001.html?uid=WEEvREc)

37
38 [ZOUNaT3NQWXc5TXptUm42ajU3VDNmbHFXTTBDTEw3UjdxZWIrWnNGeXps](http://kns.cnki.net/KCMS/detail/11.4818.R.20180207.1451.001.html?uid=WEEvREc)

39
40 [VTc3TEIGND1QUy9TYjdHNEg5](http://kns.cnki.net/KCMS/detail/11.4818.R.20180207.1451.001.html?uid=WEEvREc) (accessed 9 March 2018).

41
42
43
44
45 8. UNAIDS. Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland:
46
47 UNAIDS, 2014.

48
49
50
51 9. Zou H, Hu N, Xin Q, et al. HIV testing among men who have sex with men in
52
53 China: a systematic review and meta-analysis. *AIDS Behav* 2012;16:1717-28.

10. Zou H, Wu Z, Yu J, et al. Sexual risk behaviors and HIV infection among men who have sex with men who use the internet in Beijing and Urumqi, China. *J Acquir Immune Defic Syndr* 2010;53(Suppl 1):S81-7.
11. Wang HY, Xu JJ, Zou HC, et al. Sexual risk behaviors and HIV infection among men who have sex with men and women in China: evidence from a systematic review and meta-analysis. *BioMed Res Int* 2015;2015:850132.
12. Valdiserri RO. Late HIV diagnosis: bad medicine and worse public health. *PLoS Med* 2007;4(6):e200.
13. World Health Organization. Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services. Geneva, Switzerland: WHO, 2016.
14. Pant Pai N, Sharma J, Shivkumar S, et al. Supervised and unsupervised self-testing for HIV in high- and low-risk populations: a systematic review. *PLoS Med* 2013;10:e1001414.
15. Frye V, Wilton L, Hirshfeld S, et al. "Just because it's out there, people aren't going to use it." HIV self-testing among young, black MSM, and transgender women. *AIDS Patient Care STDS* 2015;29:617-24.
16. Bilardi J E, Walker S, Read T, et al. Gay and bisexual men's views on rapid self-testing for HIV. *AIDS Behav* 2013;17:2093-9.
17. UNAIDS. The gap report [EB/OL]. Geneva, Switzerland: UNAIDS, 2015.

- 1
2
3
4 18. Figueroa C, Johnson C, Verster A, et al. Attitudes and acceptability on HIV
5 self-testing among key populations: a literature review. *AIDS Behav* 2015;19:
6 1949-65.
7
8
9
10
11 19. Greacen T, Friboulet D, Fugon L, et al. Access to and use of unauthorised online
12 HIV self-tests by internet-using French-speaking men who have sex with men. *Sex*
13 *Transm Infect* 2012;88:368-74.
14
15
16
17 20. Wong HT, Tam HY, Chan DP, et al. Usage and acceptability of HIV self-testing in
18 men who have sex with men in Hong Kong. *AIDS Behav* 2015;19:505-15.
19
20
21
22 21. Huang E, Marlin RW, Young SD, et al. Using Grindr, a smartphone
23 social-networking application, to increase HIV self-testing among Black and Latino
24 men who have sex with men in Los Angeles, 2014. *AIDS Educ Prev* 2016;28:341-50.
25
26
27
28 22. Wei C, Yan H, Yang C, et al. Accessing HIV testing and treatment among men
29 who have sex with men in China: a qualitative study. *AIDS Care* 2014;26:372-8.
30
31
32
33 23. UNAIDS. UNAIDS Data 2017. Geneva, Switzerland : UNAIDS, 2017.
34
35
36
37 24. Katz D, Golden M, Hughes J, et al. HIV self-testing increases HIV testing
38 frequency among high-risk men who have sex with men: a randomized controlled trial
39 [abstract]. Vancouver, Canada: 8th International AIDS Society Conference, 2015.
40
41
42
43 25. Jamil MS, Prestage G, Fairley CK, et al. Effect of availability of HIV self-testing
44 on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH):
45 a waiting-list randomised controlled trial. *Lancet HIV* 2017;4:e241-e250.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26. Sharma A, Chavez P R, Macgowan R J, et al. Willingness to distribute free rapid home HIV test kits and to test with social or sexual network associates among men who have sex with men in the United States. *AIDS Care* 2017;29:1499-1503.

27. Lv LF. HIV incidence and using of oral rapid test kits for regular male sexual partner among men who have sex with men in Beijing. Hebei Medical University,

2017. [http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD201801&filename=1017826881.nh&uid=WEEvREcwSIJHSldRa1FhdXNXa0hHRXZiaHBoWVJieWNUcEdpajJMVAwMD0=\\$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4ggI8Fm4gTkoUKaID8j8gFw!!&v=MzAyODhaT1pwRkNqbFZMek1WRjI2R2JlNkdObkVycEViUEISOGVYMUx1eFITN0RoMVQzcVRyV00xRnJDVVJMS2Y=_](http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD201801&filename=1017826881.nh&uid=WEEvREcwSIJHSldRa1FhdXNXa0hHRXZiaHBoWVJieWNUcEdpajJMVAwMD0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4ggI8Fm4gTkoUKaID8j8gFw!!&v=MzAyODhaT1pwRkNqbFZMek1WRjI2R2JlNkdObkVycEViUEISOGVYMUx1eFITN0RoMVQzcVRyV00xRnJDVVJMS2Y=_)

(accessed 9 March 2018).

28. Harsha T, Samuel HM, Sue NM, et al. Promoting male partner testing and safer sexual decision-making through secondary distribution of HIV self-tests by HIV-uninfected female sex workers and women receiving antenatal and postpartum care in Kenya: a cohort study. *Lancet HIV* 2016;3: e266-74.

29. Ministry of Health of the People's Republic of China. 2016 China AIDS response progress report. 2016.

http://hunan.sina.com.cn/news/2016-11-27/detail-ifxyawmp0324958.shtml?from=hunan_ydph (accessed 9 March 2018).

30. HIV epidemic in Hunan Province at the end of October 2016 (in Chinese).

http://www.eol.cn/hunan/hunannews/201611/t20161128_1471024.shtml (accessed 9

1
2
3
4 March 2018).
5

6 31. Wang XD, Jiang CQ, Ma H. Rating scales for mental health. Beijing, MA:
7
8 Chinese journal of mental health 1999:263-266.
9

10
11
12 32. Huang ZL, Shan F, Yan RL. Analysis of HIV/AIDS high risk behavior and influencing
13
14 factors among men who have sex with men in Changsha. Practical Preventive Med
15
16 2013;20:1435-8.
17

18
19
20 33. Patel RR, Patel S, Clarke E, et al. Guidance and practice on frequency of HIV and
21
22 sexually transmitted infection testing in men who have sex with men - what is the
23
24 European situation? Int J STD AIDS 2014;25:213-8.
25

26
27
28 34. Templeton DJ, Read P, Varma R, et al. Australian sexually transmissible infection
29
30 and HIV testing guidelines for asymptomatic men who have sex with men 2014: a
31
32 review of the evidence. Sex Health 2014;11:217-29.
33

34
35
36 35. Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of oral kits for
37
38 HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in
39
40 Blantyre, Malawi. PLoS Med 2011;8:e1001102.
41

42
43
44 36. Li YF, Wang YM, Zhang RR, et al. Analysis on accuracy and influencing factors
45
46 of oral fluid-based rapid HIV self-testing among men who have sex with men.
47
48 Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2016;37:72-5.
49

50
51
52 37. Hurt CB, Powers KA. Self-testing for HIV and its impact on public health. Sex
53
54 Transm Dis 2014;41:10-2.
55

1
2
3
4 38. Yan L, Xiao P, Yan H, et al. The advance of detection technology of HIV
5 self-testing. *Chin J Prev Med* 2017;51:1053-6.
6
7

8
9 39. Alere. Alere determine HIV-1/2 quick reference card-global (English).
10

11
12 <https://www.alere.com/zh/zh/product-details/determine-hiv-1-2.html>. (accessed 9
13
14 March 2018).
15

16
17 40. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: A flexible statistical power
18 analysis program for the social, behavioral, and biomedical sciences. *Behav Res*
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

40. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: A flexible statistical power
analysis program for the social, behavioral, and biomedical sciences. *Behav Res*
Methods 2007;39:175-191.

41. Zhong F, Tang W, Cheng W, et al. Acceptability and feasibility of a social
entrepreneurship testing model to promote HIV self-testing and linkage to care among
men who have sex with men. *HIV Med* 2016;18:376-382.

42. Alere. Alere determine HIV-1/2 brochure-global (English).

<https://www.alere.com/zh/zh/product-details/determine-hiv-1-2.html> (accessed 9
March 2018)

43. Zhang C, Li X, Brecht M L, et al. Can self-testing increase HIV testing among
men who have sex with men: A systematic review and meta-analysis. *PLoS One*
2017;12:e0188890.

44. Campbell S, Klein R. Home testing to detect human immunodeficiency virus:
boon or bane? *J Clin Microbiol* 2006;44:3473-6.

45. World Health Organization. Guidance on couples HIV testing and counselling -

1
2
3 including antiretroviral therapy for treatment and prevention in serodiscordant couples:
4
5
6 recommendations for a public health approach. Geneva, Switzerland: WHO, 2012.
7

8
9 46. World Health Organization. Global health sector response to HIV, 2000-2015:
10
11 focus on innovations in Africa: progress report. Geneva, Switzerland: WHO, 2015.
12

13
14 47. Yan HJ, Yang HT, Zhao JK et al. Long-chain peer referral of men who have sex
15
16 with men: a novel approach to establish and maintain a cohort to measure HIV
17
18 incidence, Nanjing, China. *J Acquir Immune Defic Syndr* 2012;2:177-84.
19

20
21
22 48. Chen J, Li XH, Xiong Y, et al. Reducing the risk of HIV transmission among men
23
24 who have sex with men: a feasibility study of the motivational interviewing
25
26 counseling method. *Nurs Health Sci* 2016;18:400-7.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure1 Flow of recruitment and intervention.

117x147mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page Number on which item is reported
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Page 1, line2-4
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	Page17,line12 &page18,line 1
	2b	All items from the World Health Organization Trial Registration Data Set	N
Protocol version	3	Date and version identifier	N
Funding	4	Sources and types of financial, material, and other support	Page21,line2-4
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	Page20,line11-13&line18-20
	5b	Name and contact information for the trial sponsor	N
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Page13,line17-21&page18, line1-2
Introduction			

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	Page 4, line 2- page 6, line 14
	6b	Explanation for choice of comparators	N
Objectives	7	Specific objectives or hypotheses	Page 6, line 17- page 7, line 2
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	Page 8, line 17- page 9, line 4
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	Page 7, line 4- 11
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Page 8, line 1- 11
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	Page 10, line 13-page 13, line 7
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Page 13, line 3- 4
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	Page 15, line 3- 4
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	Page 11, line 10-11 & page 12, line 10-16 & page 13, line 1-7

Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	Page13, line 6-12
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Page16, line15-17
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	Page16, line 3-13
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	Page 9, line6-15
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Page 9, line20-page10, line 1-3
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Page10, line 5-10
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Page 9, line1 &page9,line10 &page20,line1-3
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Page10, line 6-8 & line10-11
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Page10, line 8-10

Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Page13, line15-21 & page14, line1-19
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Page14, line20-21 & page15, line 1-3
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Page13, line17-21
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Page15, line12-16
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Page15, line17-21
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	N
Methods: Monitoring			
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	Page13,line17-21&page18, line1-2
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	Page13, line 7

Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	Page13, line1-7
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	Page17, line18-20
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	N
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	Page 9, line12-20
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Page13, line15-21
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Page21, line7
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	N
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Page17, line20

	31b	Authorship eligibility guidelines and any intended use of professional writers	N
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	This can be accessed from Chinese Clinical Trial Registry. http://www.chictr.org.cn/edit.aspx?pid=24804&htm=4
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.